Research record / starter review

CJC-1295

Growth-hormone-releasing hormone analogue

Tested-sport concernLast reviewed 2026-07-13

Also called

CJC 1295 · growth-hormone-releasing hormone analogue

What people ask about

Community claims

growth-hormone claimsbody-composition claims

These are topics circulating in appearance, physique, or recovery communities. Listing them does not validate them.

What this record can say

Evidence snapshot

An older randomised study in healthy adults found sustained GH and IGF-I biomarker changes. It did not test muscle gain, fat loss, appearance, performance, recovery, or long-term safety; biomarker change is not a community-claim outcome.

Safety context

Read uncertainty as information

FDA describes potential immunogenicity and peptide-characterisation concerns, notes limited clinical data, and identifies serious adverse events associated with CJC-1295 in its compounding-safety table.

Tested sport

Anti-doping context

WADA's 2026 List names CJC-1295 among growth-hormone-releasing hormone analogues in S2.2.4.

Regulatory scope

Context is not a universal answer

United States: this reflects FDA's compounding-safety source, not a global legal determination.

Study-level evidence

What the individual records actually say.

Every row preserves identity and context. A related molecule, a tissue experiment, or a trial registration cannot become proof for the community claim.

Published randomised, placebo-controlled human study2006

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults ↗

Teichman SL, et al. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683. DOI: 10.1210/jc.2005-1536.

Identity: Exact compound name: CJC-1295

Design & population: Two randomised, placebo-controlled, double-blind ascending-dose studies in healthy adults aged 21–61, lasting 28 and 49 days.

Question studied: Pharmacokinetics, growth-hormone and IGF-I biomarkers, and short-term reported safety.

Record finding: The paper reports sustained, dose-dependent changes in growth-hormone and IGF-I biomarkers; no serious adverse reactions were reported in the study period.

Does not show: Biomarker changes in healthy adults do not establish changes in muscle, fat, recovery, appearance, performance, or long-term safety. This is not recent evidence.

Direct human biomarker evidence — not a relevant-outcome efficacy studyChecked 2026-07-13

Primary sources

Read the source, not only our summary.

regulatory / safetyCertain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksU.S. Food and Drug Administration ↗anti-doping2026 Prohibited ListWorld Anti-Doping Agency ↗